ClinicalTrials.gg
CompletedNCT03633058Updated May 28, 2024Results posted

A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

A Phase 2 interventional study of Ketamine in Rett Syndrome, sponsored by Rett Syndrome Research Trust. Completed at 7 sites in United States. Open to female participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Rett Syndrome Research Trust · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Enrollment
21st of 34
23 · median 32
Started
2019
with 3 others
Phase 2
10 of 55
none open now
Registered
23rd of 55
by date
Lead sponsor
5 of 55
Rett Syndrome Research Trust

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 21st largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2019, is one of 10 in phase 2, and was the 23rd registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 6 Years to 12 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort are anticipated to participate for approximately 8-10 weeks at approximately 7 US study centers.

Read the detailed description

This study is designed to assess oral ketamine for the treatment of Rett Syndrome and consists of up to 4 ascending dose cohorts, each assessing 1 dose level of ketamine vs placebo. Patients will receive in either order, a 5-day BID regimen of both placebo and the cohort-specified dose level of oral ketamine. Patients may only participate in 1 cohort. Safety and tolerability will be assessed via patient disposition, vital signs, physical examination, adverse events and concomitant medication use. Efficacy will be assessed via physician and caregiver questionnaires and assessments, and continuous, wearable, at-home biosensor data collection. An independent safety committee will review safety data from each cohort to determine if the subsequent ascending dose cohort is warranted. A total of 12 patients per cohort is anticipated at approximately 7 sites. The screening period will last between 2 and 4 weeks, the cross-over treatment period will last 4 weeks, and the safety follow-up period will last 2 weeks. Total patient participation is approximately 8-10 weeks.

03

Conditions studied

  • Rett Syndrome

Browse trials for

Keywords

  • MECP2
  • RTT
  • Retts
  • ketamine
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female Rett Syndrome patients diagnosed with Rett Syndrome with a confirmed MECP2 mutation
  • between the ages of 6 and 12, inclusive, who have not achieved menarche
  • ability to take oral medications
  • are generally healthy.

Exclusion criteria

Exclusion Criteria:

  • Patients not on stable medication regimens/other types of behavioral, educational, or dietary interventions for at least 4 weeks,
  • are taking medications that may interact with ketamine,
  • have a condition where increased blood pressure, spinal fluid pressure, or ocular pressure may put the patient at increased risk.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    0.75 mg/kg

    ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo

    Drug: Ketamine

  • Experimental
    1.5 mg/kg

    ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo

    Drug: Ketamine

Interventions

  • oral ketamine dosed twice daily for 5 days

    Also known as: Ketalar

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Adverse Events

    The Number of Participants with Treatment-emergent adverse events on ketamine compared to placebo will be summarized

    Time frame: 6 weeks

Other outcomes

  1. Continuous Biosensor Data

    2 different non-invasive, wearable devices will be used in the study to determine changes in physiologic measures for the patient in the home environment. Biosensors will be worn continuously during the screening and treatment period to measure activity, sleep, position, heart rate, and breathing.

    Time frame: 6-8 weeks

  2. Clinical Global Impression of Improvement

    Clinicians will use a 7 point Likert Scale to rate change from baseline symptom severity by addressing the question, "Compared to the patient's condition of Rett syndrome prior to treatment initiation at baseline, the patient's current condition is: 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse. No change would be scored a 0, while improvement would be scored at -1, -2, or -3 and worsening would be scored +1, +2 or +3, depending on the degree of perceived change. Negative change indicates improvement while positive change indicates worsening

    Time frame: 4 weeks

  3. Motor Behavioral Assessment

    a 37-item questionnaire for clinicians to evaluate current behavioral/social, orofacial/respiratory, and motor/physical symptoms. Each item is rated either 0 (normal or never), 1 (mild or rare), 2 (moderate or occasional), 3 (marked or frequent), 4 (very severe or constant), where higher numbers indicate higher severity. Each subscale is summed for a subscale score, while the total score is a sum of the subscale scores. The behavioral/social subscale score may range from 0 to 64; the orofacial/respiratory subscale may range from 0 to 28, and motor/physical subscale may range from 0 to 56. Total score may range from 0 to 148.

    Time frame: 4 weeks

  4. Clinician Domain Likert Scale

    an 8 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, and mood by considering the question, "Considering your experience with the patient at this visit, please rate the level of function in each category". Each domain will be rated on a 7 point Likert Scale where the clinician will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.

    Time frame: 4 weeks

  5. Rett Syndrome Behaviour Questionnaire

    a 45-item questionnaire for clinicians to evaluate current behavior and emotional features. Each item is rated either 0 (not true or not done), 1 (somewhat or sometimes true) and 2 (very true), where higher numbers indicate higher severity. Total score is summed and may range from 0 to 90.

    Time frame: 4 weeks

  6. Parent Domain Likert Scale

    a 9 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, mood, and seizure activity, by considering the question, "Considering your experience with your child over the past 7 days, please rate your child's level of function in each category". Each domain will be rated on a 7 point Likert Scale where the parent/caregiver will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.

    Time frame: 4 weeks

  7. Children's Sleep Habits Questionnaire

    a 35-item questionnaire for parents to evaluate current sleep and common sleep problems. The parent/caregiver will rate each item as 1 (rarely), 2 (sometimes), or 3 (usually), where higher scores indicate higher severity. The parent/caregiver will also indicate if the item is a problem or not. A total score of the sum of each item and 8 subscale scores (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness) are possible. Total scores between 0 and 70 are possible, where higher scores indicate more sleep problems.

    Time frame: 4 weeks

  8. Rett Caregiver Burden Inventory Assessment

    a 26-item questionnaire for parents to evaluate the burden of care on their quality of life. The parent/caregiver will rate each item as 0 (never), 1 (rarely), 2 (sometimes), 3 (quite frequently), or 4 (nearly always) where higher scores indicate higher severity. Total scores between 0 and 104 are possible, where higher scores indicate more caregiver burden.

    Time frame: 4 weeks

  9. EEG Signature

    ketamine EEG alpha, beta, gamma, delta and theta waveform signatures compared to placebo to indicate target engagement

    Time frame: Day 1, Day 15

07

Results

Posted Mar 27, 2024

Participant flow

The study was conducted at 7 sites in the US with active participants between 12Mar2019 and 22Nov2021.

Participant flow — Overall Study
Milestone0.75 mg/kg (Placebo First, Then 0.75 mg/kg Ketamine)0.75 mg/kg (0.75 mg/kg Ketamine First, Then Placebo)1.5 mg/kg (Placebo First, Then 1.5 mg/kg Ketamine)1.5 mg/kg (1.5 mg/kg Ketamine First, Then Placebo)
Started5666
Completed5656
Not completed0010
Withdrew: Adverse event0010

Outcome measures

PrimaryDose-Limiting Adverse Events

The Number of Participants with Treatment-emergent adverse events on ketamine compared to placebo will be summarized

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Dose-Limiting Adverse Events
Participants0.75 mg/kg Ketamine0.75 mg/kg Placebo1.5 mg/kg Ketamine1.5 mg/kg Placebo
TEAEs2463
SAEs0000
AEs leading to discontinuation0010
AEs leading to dose interruption0000
No TEAEs reported9759
Other pre-specifiedContinuous Biosensor Data

2 different non-invasive, wearable devices will be used in the study to determine changes in physiologic measures for the patient in the home environment. Biosensors will be worn continuously during the screening and treatment period to measure activity, sleep, position, heart rate, and breathing.

Time frame:
6-8 weeks

Results for this outcome have not been posted.

Other pre-specifiedClinical Global Impression of Improvement

Clinicians will use a 7 point Likert Scale to rate change from baseline symptom severity by addressing the question, "Compared to the patient's condition of Rett syndrome prior to treatment initiation at baseline, the patient's current condition is: 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse. No change would be scored a 0, while improvement would be scored at -1, -2, or -3 and worsening would be scored +1, +2 or +3, depending on the degree of perceived change. Negative change indicates improvement while positive change indicates worsening

Time frame:
4 weeks

Results for this outcome have not been posted.

Other pre-specifiedMotor Behavioral Assessment

a 37-item questionnaire for clinicians to evaluate current behavioral/social, orofacial/respiratory, and motor/physical symptoms. Each item is rated either 0 (normal or never), 1 (mild or rare), 2 (moderate or occasional), 3 (marked or frequent), 4 (very severe or constant), where higher numbers indicate higher severity. Each subscale is summed for a subscale score, while the total score is a sum of the subscale scores. The behavioral/social subscale score may range from 0 to 64; the orofacial/respiratory subscale may range from 0 to 28, and motor/physical subscale may range from 0 to 56. Total score may range from 0 to 148.

Time frame:
4 weeks

Results for this outcome have not been posted.

Other pre-specifiedClinician Domain Likert Scale

an 8 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, and mood by considering the question, "Considering your experience with the patient at this visit, please rate the level of function in each category". Each domain will be rated on a 7 point Likert Scale where the clinician will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.

Time frame:
4 weeks

Results for this outcome have not been posted.

Other pre-specifiedRett Syndrome Behaviour Questionnaire

a 45-item questionnaire for clinicians to evaluate current behavior and emotional features. Each item is rated either 0 (not true or not done), 1 (somewhat or sometimes true) and 2 (very true), where higher numbers indicate higher severity. Total score is summed and may range from 0 to 90.

Time frame:
4 weeks

Results for this outcome have not been posted.

Other pre-specifiedParent Domain Likert Scale

a 9 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, mood, and seizure activity, by considering the question, "Considering your experience with your child over the past 7 days, please rate your child's level of function in each category". Each domain will be rated on a 7 point Likert Scale where the parent/caregiver will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.

Time frame:
4 weeks

Results for this outcome have not been posted.

Other pre-specifiedChildren's Sleep Habits Questionnaire

a 35-item questionnaire for parents to evaluate current sleep and common sleep problems. The parent/caregiver will rate each item as 1 (rarely), 2 (sometimes), or 3 (usually), where higher scores indicate higher severity. The parent/caregiver will also indicate if the item is a problem or not. A total score of the sum of each item and 8 subscale scores (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness) are possible. Total scores between 0 and 70 are possible, where higher scores indicate more sleep problems.

Time frame:
4 weeks

Results for this outcome have not been posted.

Other pre-specifiedRett Caregiver Burden Inventory Assessment

a 26-item questionnaire for parents to evaluate the burden of care on their quality of life. The parent/caregiver will rate each item as 0 (never), 1 (rarely), 2 (sometimes), 3 (quite frequently), or 4 (nearly always) where higher scores indicate higher severity. Total scores between 0 and 104 are possible, where higher scores indicate more caregiver burden.

Time frame:
4 weeks

Results for this outcome have not been posted.

Other pre-specifiedEEG Signature

ketamine EEG alpha, beta, gamma, delta and theta waveform signatures compared to placebo to indicate target engagement

Time frame:
Day 1, Day 15

Results for this outcome have not been posted.

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 4.3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.75 mg/kg Ketamine0/11 (0%)0/11 (0%)2/11 (18.2%)
0.75 mg/kg Placebo0/11 (0%)0/11 (0%)4/11 (36.4%)
1.5 mg/kg Ketamine0/12 (0%)0/12 (0%)7/12 (58.3%)
1.5 mg/kg Placebo0/12 (0%)0/12 (0%)3/12 (25%)
Most frequent other events
Showing 10 of 21
Most frequent other events
Event0.75 mg/kg Ketamine0.75 mg/kg Placebo1.5 mg/kg Ketamine1.5 mg/kg Placebo
ConstipationGastrointestinal disorders0/111/110/121/12
VomitingGastrointestinal disorders1/111/111/121/12
Tonic convulsionNervous system disorders0/111/110/120/12
InsomniaPsychiatric disorders0/111/110/120/12
IrritabilityPsychiatric disorders0/111/111/120/12
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/110/110/120/12
DiarrhoeaGastrointestinal disorders0/110/111/120/12
EructationGastrointestinal disorders0/110/111/121/12
PyrexiaGeneral disorders0/110/111/121/12
Ear infectionInfections and infestations0/110/111/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
Mean8.6 ± 2.207.6 ± 1.938.1 ± 2.09
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
Female111223
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
Hispanic or Latino011
Not Hispanic or Latino111122
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White91120
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
United States111223
Weight
Weight(kg)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
Mean24.4 ± 7.3321.5 ± 4.6222.9 ± 6.10
Height
Height(cm)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
Mean126.0 ± 11.84117.5 ± 9.41121.7 ± 11.30
BMI
BMI(kg/m^2)All Study Participants - 0.75 mg/kg KetamineAll Study Participants - 1.5 mg/kg KetamineTotal
Mean15.1 ± 3.0615.4 ± 1.8915.2 ± 2.48
08

Study locations

7 sites
  • University of Alabama Birmingham School of Medicine
    Birmingham, Alabama 35294, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37203, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Nov 2021, 31 months.

Results were first posted in Mar 2024, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2018
First posted
Aug 16, 2018
StartActual
Mar 12, 2019
Primary completionActual
Nov 8, 2021
CompletionActual
Nov 22, 2021
Results first posted
Mar 27, 2024
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03633058
Lead sponsor
Rett Syndrome Research Trust
Responsible party
Jeffrey Neul (Director, Vanderbilt Kennedy Center, Annette Schaffer Eskind Chair, Professor of Pediatrics, Pharmacology, and Special Education, Vanderbilt University) — Principal investigator
First posted
Aug 16, 2018
Start date
Mar 12, 2019
Primary completion
Nov 8, 2021
Completion
Nov 22, 2021
Results posted
Mar 27, 2024
Last update
May 28, 2024

Study contacts

Jeffrey Neul, MD, PhD
principal investigator · Vanderbilt University Medical Center
Jana von Hehn, PhD
study director · Rett Syndrome Research Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion